Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis - Seite 2

Going forward, the Company plans to significantly reduce its expenses on ATA188 and further focus resources on advancing its differentiated allogeneic CAR-T pipeline, in addition to executing the expanded tab-cel partnership with Pierre Fabre through the Biologics License Application (BLA) transfer. These future actions are expected to meaningfully extend our cash runway beyond Q3 of 2025.

About EMBOLD

EMBOLD is a multi-national, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the safety and efficacy of ATA188 in participants with non-active progressive multiple sclerosis. The study primary analysis at 12 months included 103 adult participants with progressive multiple sclerosis (non-active PPMS and non-active SPMS).

In year one, study participants received two cycles of treatment (ATA188 or placebo) at the recommended part two dose, which was identified in part one, and were followed for 12 months, which is the timepoint for the primary endpoint. In year two, all patients received two cycles of therapy to maintain the blinding – those initially receiving placebo received ATA188 (two cycles) and those initially receiving ATA188 received one cycle of ATA188 followed by one cycle of placebo. After year two, all participants can continue into a three-year open-label extension during which they will receive annual treatment with ATA188.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X (formerly known as Twitter) and LinkedIn.